BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Leukemia AND LYL1, P12980, 4066, ENSG00000104903
69 results:

  • 1. lyl1 facilitates AETFC assembly and gene activation by recruiting CARM1 in t(8;21) AML.
    Chen Q; Cevher MA; Jiang Q; Wang S; Sun X; Roeder RG; Chen M
    Proc Natl Acad Sci U S A; 2022 Oct; 119(42):e2213718119. PubMed ID: 36215477
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. BRD4 Inhibitor GNE-987 Exerts Anticancer Effects by Targeting Super-Enhancer-Related Gene lyl1 in Acute Myeloid leukemia.
    Sang X; Zhang Y; Fang F; Gao L; Tao Y; Li X; Zhang Z; Wang J; Tian Y; Li Z; Yao D; Wu Y; Chu X; Zhang K; Ma L; Lu L; Chen Y; Yu J; Zhuo R; Wu S; Zhang Z; Pan J; Hu S
    J Immunol Res; 2022; 2022():7912484. PubMed ID: 35958877
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Super-enhancer profiling identifies novel critical and targetable cancer survival gene lyl1 in pediatric acute myeloid leukemia.
    Fang F; Lu J; Sang X; Tao YF; Wang JW; Zhang ZM; Zhang YP; Li XL; Xie Y; Wu SY; Chu XR; Li G; Wu D; Chen YL; Yu JJ; Jia SQ; Feng CX; Tian YY; Li ZH; Ling J; Hu SY; Pan J
    J Exp Clin Cancer Res; 2022 Jul; 41(1):225. PubMed ID: 35842703
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Transcriptome-wide subtyping of pediatric and adult T cell acute lymphoblastic leukemia in an international study of 707 cases.
    Dai YT; Zhang F; Fang H; Li JF; Lu G; Jiang L; Chen B; Mao DD; Liu YF; Wang J; Peng LJ; Feng C; Chen HF; Mu JX; Zhang QL; Wang H; Ariffin H; Moy TA; Wang JH; Lou YJ; Chen SN; Wang Q; Liu H; Shan Z; Matsumura I; Miyazaki Y; Yasuda T; Dou LP; Yan XJ; Yan JS; Yeoh AE; Wu DP; Kiyoi H; Hayakawa F; Jin J; Wang SY; Sun XJ; Mi JQ; Chen Z; Huang JY; Chen SJ
    Proc Natl Acad Sci U S A; 2022 Apr; 119(15):e2120787119. PubMed ID: 35385357
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Disruption of a GATA2-TAL1-ERG regulatory circuit promotes erythroid transition in healthy and leukemic stem cells.
    Thoms JAI; Truong P; Subramanian S; Knezevic K; Harvey G; Huang Y; Seneviratne JA; Carter DR; Joshi S; Skhinas J; Chacon D; Shah A; de Jong I; Beck D; Göttgens B; Larsson J; Wong JWH; Zanini F; Pimanda JE
    Blood; 2021 Oct; 138(16):1441-1455. PubMed ID: 34075404
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Convergent organization of aberrant MYB complex controls oncogenic gene expression in acute myeloid leukemia.
    Takao S; Forbes L; Uni M; Cheng S; Pineda JMB; Tarumoto Y; Cifani P; Minuesa G; Chen C; Kharas MG; Bradley RK; Vakoc CR; Koche RP; Kentsis A
    Elife; 2021 Feb; 10():. PubMed ID: 33527899
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Novel strategy for rapid functional in vivo validation of oncogenic drivers in haematological malignancies.
    Pieters T; T'Sas S; Demoen L; Almeida A; Haenebalcke L; Matthijssens F; Lemeire K; D'Hont J; Van Rockeghem F; Hochepied T; Lintermans B; Reunes L; Lammens T; Berx G; Haigh JJ; Goossens S; Van Vlierberghe P
    Sci Rep; 2019 Jul; 9(1):10577. PubMed ID: 31332244
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Review: Oncogenic Insertional Mutagenesis as a Consequence of Retroviral Gene Therapy for X-Linked Severe Combined Immunodeficiency Disease.
    Ahmed B; Zafar M; Qadir MI
    Crit Rev Eukaryot Gene Expr; 2019; 29(6):511-520. PubMed ID: 32422006
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. FDA Approval Summary: Niraparib for the Maintenance Treatment of Patients with Recurrent Ovarian Cancer in Response to Platinum-Based Chemotherapy.
    Ison G; Howie LJ; Amiri-Kordestani L; Zhang L; Tang S; Sridhara R; Pierre V; Charlab R; Ramamoorthy A; Song P; Li F; Yu J; Manheng W; Palmby TR; Ghosh S; Horne HN; Lee EY; Philip R; Dave K; Chen XH; Kelly SL; Janoria KG; Banerjee A; Eradiri O; Dinin J; Goldberg KB; Pierce WF; Ibrahim A; Kluetz PG; Blumenthal GM; Beaver JA; Pazdur R
    Clin Cancer Res; 2018 Sep; 24(17):4066-4071. PubMed ID: 29650751
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Identification of fusion genes and characterization of transcriptome features in T-cell acute lymphoblastic leukemia.
    Chen B; Jiang L; Zhong ML; Li JF; Li BS; Peng LJ; Dai YT; Cui BW; Yan TQ; Zhang WN; Weng XQ; Xie YY; Lu J; Ren RB; Chen SN; Hu JD; Wu DP; Chen Z; Tang JY; Huang JY; Mi JQ; Chen SJ
    Proc Natl Acad Sci U S A; 2018 Jan; 115(2):373-378. PubMed ID: 29279377
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Long-term observation reveals high-frequency engraftment of human acute myeloid leukemia in immunodeficient mice.
    Paczulla AM; Dirnhofer S; Konantz M; Medinger M; Salih HR; Rothfelder K; Tsakiris DA; Passweg JR; Lundberg P; Lengerke C
    Haematologica; 2017 May; 102(5):854-864. PubMed ID: 28183848
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. The Hematopoietic Transcription Factors RUNX1 and ERG Prevent AML1-ETO Oncogene Overexpression and Onset of the Apoptosis Program in t(8;21) AMLs.
    Mandoli A; Singh AA; Prange KHM; Tijchon E; Oerlemans M; Dirks R; Ter Huurne M; Wierenga ATJ; Janssen-Megens EM; Berentsen K; Sharifi N; Kim B; Matarese F; Nguyen LN; Hubner NC; Rao NA; van den Akker E; Altucci L; Vellenga E; Stunnenberg HG; Martens JHA
    Cell Rep; 2016 Nov; 17(8):2087-2100. PubMed ID: 27851970
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. SCL/TAL1 in Hematopoiesis and Cellular Reprogramming.
    Hoang T; Lambert JA; Martin R
    Curr Top Dev Biol; 2016; 118():163-204. PubMed ID: 27137657
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. The oncofusion protein FUS-ERG targets key hematopoietic regulators and modulates the all-trans retinoic acid signaling pathway in t(16;21) acute myeloid leukemia.
    Sotoca AM; Prange KH; Reijnders B; Mandoli A; Nguyen LN; Stunnenberg HG; Martens JH
    Oncogene; 2016 Apr; 35(15):1965-76. PubMed ID: 26148230
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. A population-based single nucleotide polymorphism array analysis of genomic aberrations in younger adult acute lymphoblastic leukemia patients.
    Dirse V; Bertasiute A; Gineikiene E; Zvirblis T; Dambrauskiene R; Gerbutavicius R; Juozaityte E; Malciute L; Paulsson K; Griskevicius L
    Genes Chromosomes Cancer; 2015 May; 54(5):326-33. PubMed ID: 25706938
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Expression of the potential therapeutic target CXXC5 in primary acute myeloid leukemia cells - high expression is associated with adverse prognosis as well as altered intracellular signaling and transcriptional regulation.
    Bruserud Ø; Reikvam H; Fredly H; Skavland J; Hagen KM; van Hoang TT; Brenner AK; Kadi A; Astori A; Gjertsen BT; Pendino F
    Oncotarget; 2015 Feb; 6(5):2794-811. PubMed ID: 25605239
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Enforced expression of E47 has differential effects on Lmo2-induced T-cell leukemias.
    Goodings C; Tripathi R; Cleveland SM; Elliott N; Guo Y; Shyr Y; Davé UP
    Leuk Res; 2015 Jan; 39(1):100-9. PubMed ID: 25499232
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Friend or foe: can activating mutations in NOTCH1 contribute to a favorable treatment outcome in patients with T-ALL?
    Goldshtein A; Berger M
    Crit Rev Oncog; 2014; 19(5):399-404. PubMed ID: 25404153
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Lung endothelial barrier disruption in lyl1-deficient mice.
    Pirot N; Delpech H; Deleuze V; Dohet C; Courtade-Saïdi M; Basset-Léobon C; Chalhoub E; Mathieu D; Pinet V
    Am J Physiol Lung Cell Mol Physiol; 2014 Apr; 306(8):L775-85. PubMed ID: 24532287
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. LIM domain only-2 (LMO2) induces T-cell leukemia by two distinct pathways.
    Smith S; Tripathi R; Goodings C; Cleveland S; Mathias E; Hardaway JA; Elliott N; Yi Y; Chen X; Downing J; Mullighan C; Swing DA; Tessarollo L; Li L; Love P; Jenkins NA; Copeland NG; Thompson MA; Du Y; Davé UP
    PLoS One; 2014; 9(1):e85883. PubMed ID: 24465765
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 4.